Sequential™ Unveils AI-Driven Discovery Platform for Multi-Omic Testing Innovations

Sequential™ Launches AI-Driven Discovery Platform for Skin Health

Sequential™, a pioneering company in genomic testing using non-invasive human clinical samples, recently announced the successful conclusion of its initial equity funding round, securing a significant $3.5 million in investment. This exciting development will pave the way for the creation of a cutting-edge platform focused on multi-omic testing and innovative ingredients for skin health.

The funding round was co-led by Sparkfood and Corundum Systems Biology (CSB), bringing together several prominent investors including Dermazone Holdings, SOSV, and Scrum Ventures. With this latest financing, Sequential has now raised a total of $7.5 million in both dilutive and non-dilutive funding to fuel its ambitious projects.

Sequential is on a mission to revolutionize skin health by quantifying how consumer products, pharmaceuticals, and biotechnological ingredients impact microbial and host biomarkers. Through its proprietary non-invasive analysis platform, the company transforms intricate biological data into actionable insights. By integrating microbial and molecular analyses, Sequential is able to develop credible, effective, and reliable products.

The firm boasts one of the industry’s most extensive clinical databases, featuring more than 50,000 samples, over 4,000 ingredients, and a participant base exceeding 10,000 worldwide. The newly acquired capital will be instrumental in advancing the development of an AI-based discovery engine, which will leverage Sequential's own real clinical database to predict, optimize, and discover next-generation active complexes and innovative bioactive ingredients.

Dr. Oliver Worsley, co-founder and CEO of Sequential, emphasized the company’s vision: “Our mission is to bring pharmaceutical-grade evidence and computational precision to personal care. By applying artificial intelligence to one of the world’s largest clinical datasets in dermatological health, we can uncover new skin biomarkers and go beyond incremental formulation improvements by systematically designing and validating innovative ingredient combinations.”

Anouk Veber, the head of the Ventures business unit at Sparkfood, praised Sequential's unique bridge that connects biology, clinical validation, and consumer product development. She commented, “We believe that their AI-based platform will transform how next-generation personal care products are developed and differentiated. This investment aligns with Sparkfood’s connected innovation strategy, opening doors to co-development opportunities and business synergies in the personal care sector.”

Hidehiko Otake, CEO of Corundum Systems Biology, also shared insights into the partnership: “Sequential's mission aligns perfectly with ours—to transform human health through the power of big data, the microbiome, and artificial intelligence. Our ongoing support in this round reflects our confidence in their vision and our shared commitment to redefine the future of personal care.”

By merging systems biology, advanced clinical research infrastructure, and computational modeling, Sequential aims to set a new standard in data-driven innovation within the personal care and related health categories. The company plans to continue expanding its biomarker discovery programs and global partnerships as it develops a scalable discovery platform designed to unlock the next generation of scientifically validated complexes.

In conclusion, Sequential™ is at the forefront of skin health innovation, combining intricate understanding with cutting-edge technology. Their ambitious goals are validated by substantial financial backing, and with their deep commitment to research and development, the future of personal care looks brighter than ever. For more information, visit Sequential’s website and learn how they are making strides in advancing skin health research.